Robert R. & Katherine B. Penn Associate Professor
Research in the Wang group aims to answer fundamental questions that lie at the interface of chemistry and biology. In particular, we are interested in developing small-molecule based probes and methods to understand the cause of disease with an emphasis on identifying potential therapeutic agents towards cancer and neurodegenerative disorders.
- Bioactive molecules as probes in human biology and disease. Starting from naturally occurring molecules that possess unique anti-cancer activity or neuroprotective/neurotrophic activities, our research incorporates synthetic chemistry and biological efforts to expedite discovery of novel bioactive molecules and to facilitate the study of their biological properties. Chemistry efforts will emphasize the development of modular approaches to target molecules and new methodologies to maximize synthetic efficiency. Biological studies will focus on profiling the activities of selected compounds and identifying their mode of action.
- Epigenetic modifying enzymes as novel therapeutic targets. We are interested in developing small-molecule regulators of epigenetics modifications, the new frontier in understanding and treatment of disease. For example, research will be directed towards identifying small-molecule modulators of arginine methylation and uncovering their regulatory pathways. Discovery of such molecules will provide powerful tools to interrogate the physiological roles of arginine methylation and offer potential lead molecules for novel therapies to contribute to a new era of epigenetic-based drugs.
- New chemical tools for biomolecule labeling and target identification. Our research also involves the development of new chemical tools to enable selective detection of the temporal and spatial small-molecule ligand-biomolecule interactions in vitro and in vivo. Towards this end, we will design and synthesize photoaffinity cross-linking tools to label methyltransferases, their substrates, and their binding partners.
Overall, the research in the Wang group involves the interplay of these three complementary areas and integrates the principles of synthetic chemistry, assay development, molecular and cell biology, genetics, and proteomics. Through this interdisciplinary approach, we will create a small-molecule toolbox for studying genes and pathways of importance to cancer and neurodegenerative disorders.
Appointments and Affiliations
- Robert R. & Katherine B. Penn Associate Professor
- Associate Professor of Chemistry
- Faculty Network Member of the Duke Institute for Brain Sciences
- Member of the Duke Cancer Institute
- Office Location: 2102 French Science Center, Durham, NC 27705
- Office Phone: (919) 660-1648
- Email Address: firstname.lastname@example.org
- Harvard University , 2011
- Harvard University , 2007
- Ph.D. Emory University, 2005
- B.S. Wuhan University (China), 1999
- CHEM 201DL: Organic Chemistry I
- CHEM 535: Organic Synthesis
In the News
- Two Junior Faculty Named 2016 Sloan Fellows (Feb 22, 2016)
- Kwon, Y; Wang, Q, Copper-Catalyzed 1,2-Aminocyanation of Unactivated Alkenes via Cyano Migration., Organic Letters, vol 22 no. 11 (2020), pp. 4141-4145 [10.1021/acs.orglett.0c01217] [abs].
- Park, H; Zhang, G; Bae, J; Theis, T; Warren, WS; Wang, Q, Application of 15N2-Diazirines as a Versatile Platform for Hyperpolarization of Biological Molecules by d-DNP., Bioconjugate Chemistry, vol 31 no. 3 (2020), pp. 537-541 [10.1021/acs.bioconjchem.0c00028] [abs].
- Cho, S; Wang, Q, 1,2-Difunctionalization of Aryl Triflates: A Direct and Modular Access to Diversely Functionalized Anilines., Organic Letters, vol 22 no. 4 (2020), pp. 1670-1674 [10.1021/acs.orglett.0c00320] [abs].